Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI as the first-line setting.
Yung-Sung Yeh
No relevant relationships to disclose
Meng-Lin Huang
No relevant relationships to disclose
Chien-Yu Lu
No relevant relationships to disclose
Jaw-Yuan Wang
No relevant relationships to disclose